Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

7 results
11:26 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Other Financial News

Taiho Ventures increases investment pool to $300M

March. In July, Taiho Pharmaceutical exercised an option to develop and commercialize Arcus' lead compound AB928
in Japan and other Asian territories, excluding China. AB928, an adenosine A2A receptor (ADORA2A) and ADORA2B …
9:14 AM, Jul 20, 2018  |  BC Week In Review | Company News  |  Deals

Taiho exercises option for AB928

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) exercised an option to develop and commercialize AB928 from cancer …
Option to Arcus' Candidate" ). Arcus said it is "initiating" a Phase I/Ib program for AB928
in the U.S. and Australia. Data are due in 1H19. AB928 is a dual adenosine A2A …
10:49 AM, May 11, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Arcus reports Phase I safety data for cancer candidate AB928

in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928
Chicago. The company plans to report final data from the double-blind, placebo-controlled trial in mid-2018. AB928
ADORA2A) and ADORA2B antagonist. Arcus also plans to start Phase I/Ib testing in mid-2018 of AB928
11:00 AM, Mar 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Arcus raises upsized $120M IPO

expects data next quarter from a Phase I trial in healthy volunteers of lead program AB928
12:28 PM, Nov 17, 2017  |  BC Week In Review | Financial News  |  Completed Offerings

Immuno-oncology play Arcus raises $107M

a total of $226.7 million in venture funding (see BioCentury, Sept. 5, 2016 ). Arcus' AB928
in separate Phase I monotherapy studies. Arcus plans to begin a Phase I/II study of AB928
12:52 PM, Sep 22, 2017  |  BC Week In Review | Company News  |  Deals

Taiho gets option to Arcus' candidates

additional financial terms. According to its website, Arcus expects to begin Phase I trials of AB928
next quarter and AB154 in 2Q18. AB928 is a dual adenosine A2A receptor (ADORA2A) and ADORA2B …
1:01 PM, Aug 18, 2017  |  BC Week In Review | Company News  |  Deals

Arcus gets rights to PD-1 mAb from WuXi, Gloria

BioCentury that Arcus hopes to combine the mAb with all of its portfolio candidates including AB928
CD73) inhibitor. Next year, the company plans to begin a combination trial of GLS-010 and AB928
and ADORA2B antagonist. GLS-010 is in Phase I testing in China to treat cancer, and AB928